Precision Medicine
Decoded by Data.
Windham Bio is architecting a new generation of small molecules. We leverage massive-scale genomic datasets to treat the root causes of neurodegeneration and rare metabolic disease.
Core Technology
The Windham Platform
Genetic Stratification
We use single-cell multi-omics to identify the precise sub-populations most likely to respond to our chemistry.
Bio-Structural Design
Utilizing generative AI and cryo-EM, we design molecules that hit previously undruggable pockets in complex proteins.
Translational Velocity
Our patient-derived organoid platform provides human-relevant data years before first-in-human trials.
Therapeutic Portfolio
The Clinical Pipeline
Our assets are precision-engineered to address specific genetic signatures identified through our proprietary discovery engine.
| PROGRAM | INDICATION | MODALITY | DEVELOPMENT STAGE |
|---|---|---|---|
|
WB-101
Phase 1 Ready
|
Parkinson's Disease
|
Small Molecule |
|
|
WB-204
IND-Enabling
|
Gaucher Disease & GBA-PD
|
Chaperone Therapy |
|
|
WB-307
Preclinical
|
Alzheimer's Disease
|
Immunotherapy |
|
Advancing the frontier of precision medicine through genomic intelligence and structural biology.
© 2026 Windham Bio, Inc. All Rights Reserved.